Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer.

Content Provider	Europe PMC
Author	Morelli, Cristina Formica, Vincenzo Patrikidou, Anna Rofei, Michela Shiu, Kai Keen Riondino, Silvia Argirò, Renato Floris, Roberto Ferlosio, Amedeo Orlandi, Augusto Roselli, Mario Arkenau, Hendrik-Tobias
Copyright Year	2022
Abstract	BackgroundNutritional status is strongly associated to prognosis in metastatic gastrooesophageal junction (mGOJ)/gastric cancer (GC) patients. The aim of the present study was to develop an immune-checkpoint inhibitor (ICI)-specific nutritional index (NI).MethodsTen serum and anthropometric nutritional markers derived from blood tests or CT scans were analyzed at baseline in patients treated with second-line ICI and correlated with overall survival (OS). An ICI-specific NI (the NUTRIICI) was developed with its specificity assessed in an independent group of patients treated with standard second-line chemotherapy.ResultsFrom June 2014 to December 2018, 57 mGOJ/GC patients (14 females, 43 males) with a median(m) age of 61 years (range 29–85) received ICI as second-line therapy (Pembrolizumab n=26, Nivolumab n=16, Avelumab n=15). Among the 10 analyzed variables, Onodera’s prognostic NI (PNI) ≤33 and waist-to-hip (WHR) <1 were independent predictors of OS and used to build the NUTRIICI. Patients with both favorable factors (i.e., PNI >33 and WHR ≥1, comparator group) had a mOS of 18.0 vs. 6.7 months of patients with one unfavorable factor (either PNI ≤33 or WHR <1, Hazard Ratio, HR 3.06), vs. 1.3 months of patients with both unfavorable factors (HR 17.56), overall P<0.0001. In the independent group of patients treated with standard chemotherapy NUTRIICI was not associated with prognosis (P=0.57).ConclusionsNUTRIICI is the first ICI-specific NI for mOGJ/GC patients receiving second-line ICI. A validation in larger cohorts is strongly encouraged.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9660047&blobtype=pdf
ISSN	20786891
Journal	Journal of Gastrointestinal Oncology [J Gastrointest Oncol]
Volume Number	13
DOI	10.21037/jgo-22-217
PubMed Central reference number	PMC9660047
Issue Number	5
PubMed reference number	36388663
e-ISSN	2219679X
Language	English
Publisher	AME Publishing Company
Publisher Date	2022-10-01
Access Restriction	Open
Rights License	Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Subject Keyword	Gastric cancer immunotherapy nutrition
Content Type	Text
Resource Type	Article
Subject	Gastroenterology Oncology